Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Du, Tingting ^a   Yuan, Gang ^a   Zhang, Muxun ^a   Zhou, Xinrong ^a   Sun, Xingxing ^a   Yu, Xuefeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Insulin resistance; Lipid accumulation product; TyG index; Visceral adiposity index

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; GLUCOSE INDEX; HEALTH SURVEY; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID ACCUMULATION PRODUCT INDEX; LIPID ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEX DIFFERENCE; SMOKING; SOCIOECONOMICS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY; BLOOD; INTRAABDOMINAL FAT; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; RISK;

ADIPOSITY; ADULT; APOLIPOPROTEIN A-I; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; RISK; TRIGLYCERIDES;

EID: 84964694783     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0146-3     Document Type: Article

References (40)

1. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993, 329:1988-1992.
2. Kimm H, Lee SW, Lee HS, Shim KW, Cho CY, Yun JE, Jee SH: Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. -Usefulness of lipid ratios in Korean men and women. Circ J 2010, 74:931-937.
3. Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006, 38:52-63.
4. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999, 83:25F-29F.
5. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
6. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, Hellenius ML, Fisher RM: ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007, 28:2637-2643.
7. Davidson MH: Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol 2008, 28:1582-1583.
8. Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC, investigators Fs: Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010, 53:1846-1855.
9. Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971.
10. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E: Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002, 87:5098-5103.
11. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study G: Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010, 33:920-922.
12. Kahn HS: The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 2005, 5:26.
13. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA: Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308:1150-1159.
14. Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques-Camarena O, Rodriguez-Moran M: The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemichyperinsulinemic clamp. J Clin Endocrinol Metab 2010, 95:3347-3351.
15. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F: The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 2008, 6:299-304.
16. Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, Kawata M, Yamanouchi K, Okumura T, Doi K, Tokuyama K, Nagasaka S, Fukushima M: Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism 2002, 51:544-548.
17. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A, Kishimoto H, Fukuda T, Nakaishi S, Tokuyama K, Nakai Y: Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000, 23:1766-1769.
18. Popkin BM, Du S, Zhai F, Zhang B: Cohort Profile: The China Health and Nutrition Survey-monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol 2010, 39:1435-1440.
19. Alberti KG, Zimmet P, Shaw J: Group IDFETFC: The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
20. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
21. Zhang ZQ, He LP, Xie XY, Ling WH, Deng J, Su YX, Chen YM: Association of simple anthropometric indices and body fat with early atherosclerosis and lipid profiles in Chinese adults. PLoS One 2014, 9:e104361.
22. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
23. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
24. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT: Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007, 146:640-648.
25. Hermans MP, Ahn SA, Rousseau MF: Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. Cardiovasc Diabetol 2013, 12:39.
26. Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A, Kadowaki S, Kadowaki T, Yamamoto T, Miyagawa N, Zaid M, Torii S, Takashima N, Murakami Y, Okamura T, Horie M, Ueshima H: Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. Atherosclerosis 2014, 236:237-243.
27. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003, 139:802-809.
28. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM: Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005, 96:399-404.
29. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ: Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008, 101:497-501.
30. Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism 2010, 59:299-304.
31. Stein E, Kushner H, Gidding S, Falkner B: Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome. Metabolism 2007, 56:954-960.
32. Leanca CC, Nunes VS, Panzoldo NB, Zago VS, Parra ES, Cazita PM, Jauhiainen M, Passarelli M, Nakandakare ER, de Faria EC, Quintao EC: Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects. Cardiovasc Diabetol 2013, 12:173.
33. Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF: Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res 2008, 103:159-166.
34. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
35. Tan CY, Vidal-Puig A: Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans 2008, 36:935-940.
36. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168:1609-1616.
37. Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi S, Yamamoto K: 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol 2013, 12:21.
38. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
39. Sanchez-Quesada JL, Vinagre I, De Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F, Ordonez-Llanos J, Perez A: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol 2013, 12:112.
40. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004, 27:1496-1504.